NCT06478355 - Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（ChinECR） | Biotech Hunter

Enrollment

800

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

July 1, 2025

Study Completion Date

December 31, 2025

Conditions

ESCC

Interventions

DRUG

Immunotherapy

Immunotherapy: intravenously, every 3 weeks for at least 6 months, or until progression, intolerance, or spontaneous withdrawal of the patient.

DRUG

Chemotherapy drug

TP:albumin-bound paclitaxel 110-130mg/m2,d1,d8;cis-platinum 60-75mg/m2,d1 Q3W

RADIATION

radiotherapy

Radiotherapy: Total dose of 60Gy/30 times, each time 2.0Gy, 5 times a week from week 7 to week 12 of radiotherapy.

Trial Locations (1)

Fourth Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors

lead

Hebei Medical University Fourth Hospital

OTHER